Michael A. Postow
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Cutaneous Melanoma Detection and Management
- Immunology top 0.2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 174
- Cancer Immunotherapy and Biomarkers 144
- CAR-T cell therapy research 83
- Cutaneous Melanoma Detection and Management 22
- Immunology 63
- Immunotherapy and Immune Responses 46
- Immune Cell Function and Interaction 12
- Co-authors
- Matthew D. Hellmann (12 shared papers)Robert Sidlow (2 shared papers)Jedd D. Wolchok (99 shared papers)Margaret K. Callahan (59 shared papers)Claire F. Friedman (13 shared papers)Tracy Proverbs‐Singh (1 shared paper)Mario E. Lacouture (8 shared papers)Katherine S. Panageas (49 shared papers)
- Journals
- Journal of Clinical Oncology (71 papers)Journal for ImmunoTherapy of Cancer (17 papers)Annals of Oncology (12 papers)The Oncologist (10 papers)International Journal of Radiation Oncology*Biology*Physics (8 papers)
- Partner nations
- United StatesFranceItaly
In The Last Decade
Michael A. Postow
223 papers receiving 15.6k citations
Michael A. Postow's Hit Papers
Peers
Comparison fields: 5 of 132
- Oncology 10.7k
- Immunology 4.4k
- Genetics 760
- Pulmonary and Respiratory Medicine 2.3k
- Ophthalmology 563
Countries citing papers authored by Michael A. Postow
This map shows the geographic impact of Michael A. Postow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Postow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Postow more than expected).
Fields of papers citing papers by Michael A. Postow
This network shows the impact of papers produced by Michael A. Postow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Postow. The network helps show where Michael A. Postow may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael A. Postow, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 236 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Immune-Related Adverse Events Associated with Immune Checkpoint Blockade Hit paper breakdown → | 2018 | 3348 |
| 2 | Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies Hit paper breakdown → | 2015 | 1196 |
| 3 | Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center Hit paper breakdown → | 2015 | 815 |
| 4 | Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors Hit paper breakdown → | 2016 | 635 |
| 5 | MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma Hit paper breakdown → | 2018 | 415 |
| 6 | 2016 | 359 | |
| 7 | 2016 | 315 | |
| 8 | 2015 | 314 | |
| 9 | 2017 | 313 | |
| 10 | Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment Hit paper breakdown → | 2015 | 310 |
| 11 | 2015 | 288 | |
| 12 | Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies Hit paper breakdown → | 2016 | 269 |
| 13 | 2016 | 231 | |
| 14 | 2017 | 217 | |
| 15 | 2016 | 201 | |
| 16 | 2019 | 179 | |
| 17 | 2016 | 177 | |
| 18 | 2015 | 176 | |
| 19 | 2013 | 146 | |
| 20 | 2016 | 145 |
About Michael A. Postow
Michael A. Postow is a scholar working on Oncology, Immunology, Molecular Biology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 236 papers that have together received 15.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (144 papers), CAR-T cell therapy research (83 papers), Immunotherapy and Immune Responses (46 papers), Melanoma and MAPK Pathways (41 papers), Cutaneous Melanoma Detection and Management (22 papers), Brain Metastases and Treatment (19 papers), Immune Cell Function and Interaction (12 papers) and Ocular Oncology and Treatments (12 papers). The work is most often cited by research in Oncology (10.7k citations), Immunology (4.4k citations), Genetics (760 citations), Pulmonary and Respiratory Medicine (2.3k citations) and Ophthalmology (563 citations). Michael A. Postow has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Matthew D. Hellmann, Robert Sidlow, Jedd D. Wolchok, Margaret K. Callahan, Claire F. Friedman, Tracy Proverbs‐Singh, Mario E. Lacouture, Katherine S. Panageas, Richard D. Carvajal and Katja Schindler. Their work appears in journals such as Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, Annals of Oncology, The Oncologist and International Journal of Radiation Oncology*Biology*Physics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.